ArticlePediatric pulmonology2025
Persistent Low-Output Neonatal Chylothorax: How Long Are We Justified to Wait for Pleurodesis in Partial Responders?
Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Persistent Low-Output Neonatal Chylothorax: How Long Are We Justified to Wait for Pleurodesis in Partial Responders?Pediatric pulmonology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsThe aim of our study was to review our experience regarding the management of neonatal chylothorax, with particular focus on outcomes of partial responders.
methodsWe conducted a retrospective analysis of neonatal chylothorax cases between January 2015 and December 2023. First-line management included drainage, fasting, parenteral nutrition, and octreotide. Good responders had a drainage output of <2 ml/kg/day after 1 week; partial responders had 2-10 ml/kg/day, and non-responders had >10 ml/kg/day or >100 ml/day for 5 days with complications. Partial responders continued conservative management, while non-responders received second-line treatment with bedside iodopovidone chemical pleurodesis.
resultsThirty-five newborns (15 females, 20 males) were diagnosed with chylothorax, 11 congenital and 24 acquired (18 CDH, 5 esophageal atresia, 1 caval thrombosis). After first-line treatment, 7 (20%) were good responders, 19 (54%) were partial responders, and 9 (26%) were non-responders. Non-responders received iodopovidone pleurodesis, which resolved the condition in all cases (median time to resolution was 4 days). Complications during hospitalization included 8 cases of sepsis (1 fatal), 5 of atelectasis (4 related to pleurodesis), and 4 venous thromboses. Partial responders had significantly more sepsis (p = 0.029) but less atelectasis (p = 0.025) compared to non-responders, with similar resolution times and hospital stays. After a median follow-up of 3 years, there were no recurrences or thyroid dysfunction in the iodopovidone group.
conclusionsFirst-line conservative management, although initially appropriate, can lead to serious morbidity if prolonged. Timely second-line treatment for partial responders with low-output chylothorax can minimize morbidity and mortality. Bedside chemical pleurodesis with iodopovidone is a safe and effective second-line treatment for refractory neonatal chylothorax.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.